(Q38850605)

7 September 2017

1 reference

title

Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer (English)

1 reference

Beatrice Mohelnikova-Duchonova

7 September 2017

1 reference

series ordinal

3

object named as

Beatrice Mohelnikova-Duchonova

0 references

author name string

Radmila Lemstrova

series ordinal

1

1 reference

PubMed ID

27250969

7 September 2017

Bohuslav Melichar

series ordinal

2

1 reference

7 September 2017

1 June 2016

1 reference

Cancer Chemotherapy and Pharmacology

7 September 2017

1 reference

7 September 2017

78

1 reference

7 September 2017

6

1 reference

7 September 2017

1101-1111

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-016-3058-y

7 September 2017

0 references

cites work

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Promotion of microtubule assembly in vitro by taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Pharmacogenetic pathway analysis of docetaxel elimination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Clinical pharmacokinetics of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Hypersensitivity reactions from taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Albumin-bound paclitaxel: a next-generation taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Role of solute carrier transporters in pancreatic cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

CYP2A13, ADH1B, and ADH1C gene polymorphisms and pancreatic cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Mechanisms of Taxol resistance related to microtubules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Survivin, versatile modulation of cell division and apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Prognostic relevance of survivin in pancreatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Survivin expression and serum levels in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

A starring role for stellate cells in the pancreatic cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Pancreatic cancer: the role of pancreatic stellate cells in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Pancreatic cancer biology and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3058-Y

10.1007/S00280-016-3058-Y

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

27250969

Dimensions Publication ID

7 September 2017

0 references

1 reference

PubMed ID

27250969